Comparing Kymriah vs Tecartus
| Kymriah (tisagenlecleucel) | Tecartus (brexucabtagene autoleucel) |
|
|---|
| Kymriah (tisagenlecleucel) | Tecartus (brexucabtagene autoleucel) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. Kymriah may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma. Tecartus may also be used for purposes not listed in this medication guide. |
Related suggestions Acute Lymphoblastic Leukemia
Popular comparisons
|
|||||||
| More about Kymriah (tisagenlecleucel) | More about Tecartus (brexucabtagene autoleucel) | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Kymriah side effects |
View all Tecartus side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Kymriah prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
403.2 hours |
N/A |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 264 drugs are known to interact with Kymriah:
|
A total of 307 drugs are known to interact with Tecartus:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Monjuvi
Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma (FL) in adults. It is a p ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Tazverik
Tazverik (tazemetostat) used for the treatment of patients with epithelioid sarcoma and follicular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.